Who are combination of Ketamine and Propofol's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Namenda, Felbatol, QUINIDINE, Methadone Hydrochloride, Intravenous anesthetic, Ketamine plus usual care.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/combination-of-ketamine-and-propofol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

combination of Ketamine and Propofol — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

combination of Ketamine and Propofol (combination of Ketamine and Propofol) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anesthetic. Area: Anesthesiology.

phase 3 Anesthetic NMDA receptor Anesthesiology Small molecule Live · refreshed every 30 min

Target snapshot

combination of Ketamine and Propofol (combination of Ketamine and Propofol) — Nantes University Hospital. Ketamine and Propofol work together to induce general anesthesia by modulating NMDA receptors and inhibiting GABA uptake.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
combination of Ketamine and Propofol TARGET	combination of Ketamine and Propofol	Nantes University Hospital	phase 3	Anesthetic	NMDA receptor
Namenda	MEMANTINE	AbbVie	marketed	N-methyl-D-aspartate Receptor Antagonist	Glutamate NMDA receptor; GRIN1/GRIN2A	2003-01-01
Felbatol	FELBAMATE	Mylan Speciality Lp	marketed	Anti-epileptic Agent [EPC]	NMDA receptor-ionophore complex	1993-01-01
QUINIDINE	QUINIDINE		marketed		sigma-1 receptor, NMDA receptor, CYP2D6	1950-01-01
Methadone Hydrochloride	METHADONE	Specgx Llc	marketed	Opioid Agonist	mu-opioid receptors, NMDA receptor	1947-01-01
Intravenous anesthetic	Intravenous anesthetic	University of Pennsylvania	marketed	GABA-A receptor agonist / NMDA receptor antagonist (class-dependent)	GABA-A receptor or NMDA receptor (varies by specific agent)
Ketamine plus usual care	Ketamine plus usual care	The University of Texas Health Science Center, Houston	marketed	NMDA receptor antagonist	NMDA receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anesthetic class)

Express Specialty Pharmacy · 1 drug in this class
Nantes University Hospital · 1 drug in this class
The University of Texas Health Science Center, Houston · 1 drug in this class
Universidad de Colima · 1 drug in this class
University Hospital, Montpellier · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). combination of Ketamine and Propofol — Competitive Intelligence Brief. https://druglandscape.com/ci/combination-of-ketamine-and-propofol. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab